https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Medical Service Utilization and Direct Medical Cost of Stroke in Urban China https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45188 Wed 26 Oct 2022 14:46:49 AEDT ]]> Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53350 75% decline), the ratio of incident cases to number of people living with HIV (incidence-to-prevalence ratio threshold <0·03), and the ratio of incident cases to deaths (incidence-to-mortality ratio threshold <1·0). Findings: In 2019, there were 36·8 million (95% uncertainty interval [UI] 35·1–38·9) people living with HIV worldwide. There were 0·84 males (95% UI 0·78–0·91) per female living with HIV in 2019, 0·99 male infections (0·91–1·10) for every female infection, and 1·02 male deaths (0·95–1·10) per female death. Global progress in incident cases and deaths between 2010 and 2019 was driven by sub-Saharan Africa (with a 28·52% decrease in incident cases, 95% UI 19·58–35·43, and a 39·66% decrease in deaths, 36·49–42·36). Elsewhere, the incidence remained stable or increased, whereas deaths generally decreased. In 2019, the global incidence-to-prevalence ratio was 0·05 (95% UI 0·05–0·06) and the global incidence-to-mortality ratio was 1·94 (1·76–2·12). No regions met suggested thresholds for progress. Interpretation: Sub-Saharan Africa had both the highest HIV burden and the greatest progress between 1990 and 2019. The number of incident cases and deaths in males and females approached parity in 2019, although there remained more females with HIV than males with HIV. Globally, the HIV epidemic is far from the UNAIDS benchmarks on progress metrics. Funding: The Bill & Melinda Gates Foundation, the National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH.]]> Wed 22 Nov 2023 10:32:54 AEDT ]]> An overview of evidence- and value-based economic evaluation for health care in chronic disease https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35082 Wed 19 Jun 2019 17:05:48 AEST ]]> Posttraumatic stress disorder among deliberate self-poisoning patients https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15322 Wed 11 Apr 2018 17:07:37 AEST ]]> Travelling all over the countryside: travel-related burden and financial difficulties reported by cancer patients in New South Wales and Victoria https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:13558 Sat 24 Mar 2018 10:35:33 AEDT ]]> Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1806 Sat 24 Mar 2018 08:27:29 AEDT ]]> What difference a decade? The costs of psychosis in Australia in 2000 and 2010: comparative results from the first and second Australian national surveys of psychosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18308 Sat 24 Mar 2018 08:04:40 AEDT ]]> Estimating the lifetime economic burden of Parkinson's disease in Singapore https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18930 Sat 24 Mar 2018 07:59:00 AEDT ]]> Cost of illness of chronic hepatitis B infection in Vietnam https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:20895 Sat 24 Mar 2018 07:57:53 AEDT ]]> Burden of epilepsy: a prevalence-based cost of illness study of direct, indirect and intangible costs for epilepsy https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:23416 Sat 24 Mar 2018 07:13:53 AEDT ]]> Burden of rheumatoid arthritis from a societal perspective: a prevalence-based study on cost of illness for patients with rheumatoid arthritis in China https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36021 Fri 24 Jan 2020 16:36:08 AEDT ]]>